Anthropic has added a heavyweight from the pharmaceutical world to its board of directors. The company's Long-Term Benefit Trust appointed Vas Narasimhan — physician-scientist and CEO of Novartis — on April 14, making him the first pharmaceutical industry executive to serve on the AI safety company's governing body.
The move carries outsized governance implications: trust-appointed directors now constitute a majority of Anthropic's seven-member board, which also includes co-founders Dario and Daniela Amodei alongside Yasmin Razavi, Jay Kreps, Reed Hastings, and Chris Liddell.
A Governance Signal Ahead of IPO
The appointment comes as Anthropic is widely expected to pursue an initial public offering later this year. Board composition matters enormously in pre-IPO positioning, and installing an independent majority through the Trust sends a clear message: Anthropic intends to demonstrate that safety-oriented governance can coexist with commercial scale.
The Long-Term Benefit Trust is an independent body whose members hold no financial stake in Anthropic. It exists to balance the company's financial ambitions with its public benefit mission of developing AI for humanity's long-term benefit. With Narasimhan's addition, that body now controls the board's direction.
"Getting powerful new technology to people safely and at scale is what we think about every day at Anthropic," said company president Daniela Amodei.
Why a Pharma CEO?
Narasimhan has overseen the development and approval of more than 35 novel medicines over the course of his career, including his leadership of one of the world's largest innovative medicines companies. Earlier in his career, he worked on HIV/AIDS, malaria, and tuberculosis programs in developing regions. He is an elected member of the US National Academy of Medicine and serves on the University of Chicago board of trustees and Harvard Medical School's board of fellows.
"Anthropic is setting the standard for how AI should be developed to benefit humanity, and I'm honored to join," Narasimhan said.
The appointment aligns with Anthropic's growing healthcare focus. The company has already partnered with pharmaceutical companies including Novo Nordisk and Genmab to explore how AI can accelerate drug development timelines and improve patient outcomes.
Broader Implications
The parallels between pharmaceutical regulation and AI governance are not lost on industry observers. Drug development operates under some of the strictest safety and testing regimes in any industry — exactly the kind of institutional knowledge that could inform how frontier AI models are evaluated and deployed.
For Anthropic, the appointment reinforces a narrative that responsible AI development is not just a marketing position but a structural commitment embedded in corporate governance. Whether that framing holds up under the pressures of public markets remains the central question as the company approaches what could be one of the most closely watched IPOs of 2026.
